-
1.
Where does Münch flow begin? Sucrose transport in the pre-phloem path.
Rockwell, FE, Gersony, JT, Holbrook, NM
Current opinion in plant biology. 2018;:101-107
Abstract
Current conceptions of sucrose export largely neglect the effect of transpiration-induced water potential gradients within leaf mesophyll, even as the mix of convection and diffusion in the pre-phloem path remains uncertain. It is also generally held that the relative importance of convection and diffusion in the pre-phloem path is controlled by the ratio of their respective mass transfer coefficients. Here, we consider pre-phloem sucrose transport in the presence of adverse water potential gradients, finding that whether convection impedes or aids sucrose delivery to the phloem is independent of the permeability of the plasmodesmata to bulk flow, and depends only on assimilation rate, path-length, and the diffusivity. For most tissues subject to transpiration, convection through plasmodesmata pushes sugar away from the phloem.
-
2.
Sea buckthorn decreases and delays insulin response and improves glycaemic profile following a sucrose-containing berry meal: a randomised, controlled, crossover study of Danish sea buckthorn and strawberries in overweight and obese male subjects.
Mortensen, MW, Spagner, C, Cuparencu, C, Astrup, A, Raben, A, Dragsted, LO
European journal of nutrition. 2018;(8):2827-2837
Abstract
PURPOSE Berries and mixed berry products exert acute effects on postprandial glycaemia and insulinemia, but very few berries have been studied, and primarily in normal weight subjects. Sea buckthorn and strawberry are compositionally widely different berries and may likely produce different responses. The effects of strawberry and sea buckthorn on postprandial glycaemia and insulinemia were examined in overweight or obese male subjects. Subjective appetite sensations and ad libitum intake were also examined. METHODS The study was conducted as a randomised, controlled, single-blinded, three-way crossover study. Eighteen subjects were studied in three 2-h meal tests followed by a subsequent ad libitum meal. Test meals contained added sucrose and either sea buckthorn, strawberry or no berries with added fructose (control). Blood samples were collected at t = 0, 30, 45, 60, 90 and 120 min. Subjective appetite sensations were recorded at t = 0, 15, 30, 45, 60, 90, 120, and 140 min and subsequent ad libitum intake was recorded. Statistical differences in all continuous measures were evaluated based on the existence of a meal or a time-meal interaction by repeated measures linear model analyses or by differences in AUC by linear mixed models. RESULTS None of the berries affected postprandial glucose. However, sea buckthorn improved glycaemic profile (44.7%, p < 0.01) compared to control. Sea buckthorn also resulted in a decrease in plasma insulin concentration at 30 min (39.6%, p < 0.01) and at 45 min (16.5%, p < 0.05) compared to control and the maximal increase in plasma insulin was lower following sea buckthorn compared with control (23.6%, p < 0.01). Strawberry did not affect postprandial insulin concentrations compared to control. No differences between control and each of the two berries were observed for any of the appetite parameters, except for desire for something sweet, which was increased following the sea buckthorn meal compared to control. CONCLUSIONS There was no effect on postprandial glucose response to a sugar challenge given together with purees of strawberry or sea buckthorn. Sea buckthorn decreased and delayed the insulin response and improved glycaemic profile compared with control. Strawberry had no such effects. No important differences were seen for the appetite measures. Sea buckthorn might be useful as a culinary tool for lowering meal insulin response.
-
3.
Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.
Otsuki, T, Utsunomiya, K, Moriuchi, M, Horikoshi, S, Okamura, M, Suzuki, H, Okamura, M, Maruyama, N, Shibahara, N, Abe, M
Nephron. 2018;(3):161-168
Abstract
OBJECTIVE This study investigated the effects of sucroferric oxyhydroxide on fibroblast growth factor (FGF)-23 and dose reduction of erythropoiesis-stimulating agents (ESA) and intravenous saccharated ferric oxide in hemodialysis patients. METHODS In this prospective, open-label, parallel-group, multicenter trial involving patients receiving lanthanum carbonate hydrate, eligible patients were randomized to a sucroferric oxyhydroxide group or a control group. Hemoglobin, serum phosphate, FGF-23, iron, and ferritin levels, as well as transferrin saturation, doses of intravenous saccharated ferric oxide and ESA administered, and the erythropoietin responsiveness index (ERI) were monitored for 24 weeks. RESULTS Sixty-eight eligible patients were allocated to receive sucroferric oxyhydroxide (n = 34) or serve as controls (n = 34). Data for 31 patients in the sucroferric oxyhydroxide group and 32 in the control group were analyzed. Serum phosphate was equally well controlled in both groups. In the sucroferric oxyhydroxide group, intact FGF-23 levels decreased significantly from baseline at the end of the study (p = 0.01) and there was a significant difference compared with the control group (p = 0.035). Required doses of ESA and ERI were significantly reduced in the sucroferric oxyhydroxide group decreased significantly. The dose of intravenous saccharated ferric oxide required in the sucroferric oxyhydroxide group was significantly lower than that at baseline (p = 0.006) and in the control group (p = 0.003). CONCLUSIONS Treatment of hyperphosphatemia with sucroferric oxyhydroxide was effective in patients on hemodialysis, resulting in decreased serum FGF-23 levels and a reduction in the required dose of saccharated ferric oxide.
-
4.
Active Acupoints Differ from Inactive Acupoints in Modulating Key Plasmatic Metabolites of Hypertension: A Targeted Metabolomics Study.
Yang, M, Yu, Z, Chen, X, Guo, Z, Deng, S, Chen, L, Wu, Q, Liang, F
Scientific reports. 2018;(1):17824
Abstract
The effect of active acupoints versus inactive acupoints in treating hypertension is not well documented. Metabolic phenotypes, depicted by metabolomics analysis, reflect the influence of external exposures, nutrition, and lifestyle on the integrated system of the human body. Therefore, we utilized high-performance liquid chromatography tandem mass spectrometry to compare the targeted metabolic phenotype changes induced by two different acupoint treatments. The clinical outcomes show that active acupoint treatment significantly lowers 24-hour systolic blood pressure but not diastolic blood pressure, as compared with inactive acupoint treatment. Furthermore, distinctive changes are observed between the metabolomics data of the two groups. Multivariate analysis shows that only in the active acupoint treatment group can the follow-up plasma be clearly separated from the baseline plasma. Moreover, the follow-up plasma of these two groups can be clearly separated, indicating two different post-treatment metabolic phenotypes. Three metabolites, sucrose, cellobiose, and hypoxanthine, are shown to be the most important features of active acupoint treatment. This study demonstrates that metabolomic analysis is a potential tool that can be used to efficiently differentiate the effect of active acupoints from inactive acupoints in treating hypertension. Possible mechanisms are the alternation of hypothalamic microinflammation and the restoration of host-gut microbiota interactions induced by acupuncture.
-
5.
Randomised crossover trial showed that using breast milk or sucrose provided the same analgesic effect in preterm infants of at least 28 weeks.
Collados-Gómez, L, Ferrera-Camacho, P, Fernandez-Serrano, E, Camacho-Vicente, V, Flores-Herrero, C, García-Pozo, AM, Jiménez-García, R
Acta paediatrica (Oslo, Norway : 1992). 2018;(3):436-441
Abstract
AIM: Repeated, ongoing exposure to pain influences the growth, cognitive and motor functions, behaviour, personality and neurodevelopment of preterm infants. We compared the analgesic effects of expressed breast milk (EBM) and 24% oral sucrose on preterm neonates during venipuncture. METHODS This multicentre randomised, noninferiority, crossover trial focused on five neonatal university units in Madrid, Spain, from October 2013 to October 2014. It comprised 66 preterm infants born at less than 37 weeks and randomly split into two groups. They received either EBM or sucrose two minutes before venepuncture, together with nonnutritive sucking and swaddling, then the opposite procedure at a later point. Pain was measured with the premature infant pain profile (PIPP) and crying was also measured. RESULTS There were no statistically significant differences between the groups. The PIPP scores were seven (4-9) with breast milk and six (4-8.25) with sucrose (p = 0.28). The 11 infants born at under 28 weeks of age showed higher median scores of nine (9-14) for breast milk and four (4-7) for sucrose (p = 0.009). CONCLUSION EBM and 24% sucrose had the same analgesic effect during venipuncture in most of the preterm neonates, but sucrose worked better in extremely preterm infants.
-
6.
Biotechnological potential of novel glycoside hydrolase family 70 enzymes synthesizing α-glucans from starch and sucrose.
Gangoiti, J, Pijning, T, Dijkhuizen, L
Biotechnology advances. 2018;(1):196-207
Abstract
Transglucosidases belonging to the glycoside hydrolase (GH) family 70 are promising enzymatic tools for the synthesis of α-glucans with defined structures from renewable sucrose and starch substrates. Depending on the GH70 enzyme specificity, α-glucans with different structures and physicochemical properties are produced, which have found diverse (potential) commercial applications, e.g. in food, health and as biomaterials. Originally, the GH70 family was established only for glucansucrase enzymes of lactic acid bacteria that catalyze the synthesis of α-glucan polymers from sucrose. In recent years, we have identified 3 novel subfamilies of GH70 enzymes (designated GtfB, GtfC and GtfD), inactive on sucrose but converting starch/maltodextrin substrates into novel α-glucans. These novel starch-acting enzymes considerably enlarge the panel of α-glucans that can be produced. They also represent very interesting evolutionary intermediates between sucrose-acting GH70 glucansucrases and starch-acting GH13 α-amylases. Here we provide an overview of the repertoire of GH70 enzymes currently available with focus on these novel starch-acting GH70 enzymes and their biotechnological potential. Moreover, we discuss key developments in the understanding of structure-function relationships of GH70 enzymes in the light of available three-dimensional structures, and the protein engineering strategies that were recently applied to expand their natural product specificities.
-
7.
Evolution of Sucrose Metabolism: The Dichotomy of Invertases and Beyond.
Wan, H, Wu, L, Yang, Y, Zhou, G, Ruan, YL
Trends in plant science. 2018;(2):163-177
Abstract
In higher plants, invertases hydrolyze sucrose (Suc), the major end product of photosynthesis, into glucose (Glc) and fructose (Fru), which are used as nutrients, energy sources, and signaling molecules for plant growth, yield formation, and stress responses. The invertase enzymes, named CWINs, VINs, and CINs, are located in the cell wall, vacuole, and cytosol, respectively. We hypothesize, based on their distinctive subcellular locations and physiological roles, that invertases may have undergone different modes during evolution with important functional implications. Here, we provide phylogenetic and functional genomic evidence that CINs are evolutionarily and functionally more stable compared with CWINs and VINs, possibly reflecting their roles in maintaining cytosolic sugar homeostasis for cellular function, and that CWINs have coevolved with the vasculature, likely as a functional component of phloem unloading.
-
8.
Enhanced biosynthesis of dextransucrase: A multivariate approach to produce a glucosyltransferase for biocatalysis of sucrose into dextran.
Zafar, SB, Asif, T, Qader, SAU, Aman, A
International journal of biological macromolecules. 2018;:776-785
Abstract
The current study reported the statistically designed experimental method to enhance the biocatalytic efficacy of dextransucrase from Weissella confusa. Various environmental and nutritional parameters were optimized using multiple responses under submerged fermentation environment. Statistical models were constructed to screen the influence of nine factors on the biocatalysis of dextransucrase. Among them, fermentation time, pH, sucrose and peptone exhibited significant probability (P < 0.05) and are considered as substantial constituents in accordance with Plackett-Burman design. Central composite design was further implemented to optimize the levels of selected variables for maximum enzyme yield. The predicted optimum conditions were pH of 7.5 under fermentation time of 8 h with 30.0 g l-1 sucrose and 1.0 g l-1 peptone. The overall enzyme yield increased from 11.4 DSU ml-1 to 52.75 DSU ml-1 with 4.62-fold upsurge after the implementation of the statistical models. Furthermore, SEM analysis showed the biocatalytic conversion of sucrose into highly porous dextran when utilizing dextransucrase. The biopolymer produced under the current optimized model could be utilized as an emulsifying, gelling, stabilizing and thickening agent in food industry.
-
9.
Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
Isaka, Y, Fujii, H, Tsujimoto, Y, Teramukai, S, Hamano, T
Clinical and experimental nephrology. 2018;(4):967-972
-
-
Free full text
-
Abstract
BACKGROUND In dialysis patients, mortality risk due to cardiovascular diseases is remarkably high and prognosis is poor; coronary artery calcification is considered one of the major contributing factors. It is known that hyperphosphatemia is associated with coronary artery calcification. Therefore, controlling serum phosphate level and thereby mitigating vascular calcification could improve the poor prognosis of dialysis patients. However, the optimal phosphate level in dialysis patients remains unknown; hence, this study was planned to compare the effects of two types of non-calcium-based phosphate binders, and examine the effect of strict control of phosphate on coronary artery calcification. METHODS EPISODE is a randomized, open-label, multi-center, interventional trial with a two-by-two factorial design (UMIN ID UMIN000023648). This trial will enroll hemodialysis patients who have been on dialysis for at least 3 months with a pre-dialysis serum phosphate level of at least 5.0 mg/dL or at least 6.1 mg/dL, respectively, in those taking or not taking a phosphate binder, as measured during the observation period. Registered patients will be randomized to the sucroferric oxyhydroxide or lanthanum carbonate arm and will receive the assigned drug to reduce serum phosphate to two target levels (3.5-4.5 mg/dL in strict arm and 5.0-6.0 mg/dL in standard arm) for 12 months. The primary endpoint will be percent change in coronary artery calcification score, and the secondary endpoints will include change from baseline serum phosphate and calcium levels, change in renal anemia-related factors, etc. The desired sample size has been calculated to be 200 patients.
-
10.
[Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?].
Bataille, P, Delattre, V, Daroux, M
Nephrologie & therapeutique. 2017;:S103-S108
Abstract
International guidelines suggest lowering elevated phosphorus level to the normal range in patients on dialysis. Among the phosphate-lowering strategies, phosphate binder is frequently used in addition to dietary phosphate restriction and an adequate dialysis strategy. However, serum phosphate concentration higher than 1.78mmol/L is observed in more than 40% of patients justifying the quest for new drugs. Sucroferric oxyhydroxide is one of the new iron-based agents and is available in France since May 2016. A recent international multicentre study showed this new drug to be as efficacious and non-inferior to sevelamer carbonate in magnitude of serum phosphate control. The serum phosphorus-lowering effect was maintained over 1year. When compared to carbonate sevelamer, the pill-burden was half with sucroferric oxyhydroxide because of its high phosphate binding capacity. As previously shown by experimental studies, no risk of iron accumulation was observed since iron absorption is negligible. Discolored feces and diarrhea were fairly frequent side effects. When diarrhea subsides, the tolerability of this new phosphate binder is excellent on a long-term basis.